Duloxetine Treatment of Pediatric Chronic Pain and Co-Morbid Major Depressive Disorder

2007 ◽  
Vol 17 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Karen G. Meighen
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Pediatric Chronic Pain

Alternative diagnostic criteria for major depressive disorder in patients with chronic pain

Pain ◽  
2001 ◽  
Vol 91 (3) ◽  
pp. 227-234 ◽  
Author(s):  
Keith G. Wilson ◽  
Samuel F. Mikail ◽  
Joyce L. DʼEon ◽  
Joanne E. Minns
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Diagnostic Criteria ◽  
Major Depressive

scholarly journals Major Depressive Disorder and Sleep Disturbance in Patients with Chronic Pain

2014 ◽  
Vol 19 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Patricia C Emery ◽  
Keith G Wilson ◽  
John Kowal
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Sleep Hygiene ◽  
Dysfunctional Beliefs ◽  
Major Depressive ◽  
Hygiene Practices ◽  
Chronic Pain Patients ◽  
Pain Patients ◽  
Presleep Arousal

BACKGROUND: Disturbed sleep is a common problem in both chronic pain and major depressive disorder (MDD). Moreover, many patients with chronic pain are depressed.OBJECTIVES: To examine the effects of depression on the sleep behaviour of chronic pain patients by comparing patients who did or did not meet diagnostic criteria for MDD.METHODS: A total of 60 patients with chronic musculoskeletal pain underwent structured diagnostic interviews for MDD and insomnia, and completed questionnaires assessing pain severity, disability, sleep quality, beliefs and attitudes about sleep, and sleep hygiene. For four consecutive days, they also completed a sleep diary, and reported on sleep hygiene practices and presleep arousal.RESULTS: Thirty-three patients (55%) met diagnostic criteria for MDD, most of whom (n=32 [97%]) also fulfilled criteria for insomnia disorder. Insomnia was also common among patients without MDD (21 of 27 [78%]). Participants with MDD had higher self-reports of pain, disability, dysfunctional beliefs about sleep, and, on a prospective basis, greater presleep arousal and poorer sleep hygiene. However, diary assessments of specific sleep parameters (eg, sleep onset latency, total sleep time, sleep efficiency) did not differ between the groups.DISCUSSION: Chronic pain patients with comorbid MDD exhibited more dysfunctional beliefs about sleep, poorer sleep hygiene practices and greater presleep arousal; however, diary-recorded sleep characteristics may not differ from those of patients without MDD. Chronic pain itself may disturb sleep so extensively that MDD introduces little additive effect.CONCLUSION: MDD in chronic pain may be related to the cognitive and behavioural aspects of insomnia, rather than to an incremental disturbance in the initiation or maintenance of sleep.

scholarly journals Identification of novel common variants associated with chronic pain using conditional false discovery rate analysis with major depressive disorder and assessment of pleiotropic effects of LRFN5

2018 ◽  
Author(s):  
Keira J.A. Johnston ◽  
Mark J. Adams ◽  
Barbara I. Nicholl ◽  
Joey Ward ◽  
Rona J Strawbridge ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
False Discovery Rate ◽  
Complex Traits ◽  
Pleiotropic Effects ◽  
Chromosome 1 ◽  
Chromosome 14 ◽  
Major Depressive ◽  
False Discovery

AbstractChronic pain is highly prevalent worldwide, with a significant socioeconomic burden, and also contributes to excess mortality. Chronic pain is a complex trait that is moderately heritable and genetically, as well as phenotypically, correlated with major depressive disorder (MDD). Use of the Conditional False Discovery Rate (cFDR) approach, which leverages pleiotropy identified from existing GWAS outputs, has been successful in discovering novel associated variants in related phenotypes. Here, genome-wide association study outputs for both von Korff chronic pain grade as a quasi-quantitative trait and for MDD were used to identify variants meeting a cFDR threshold for each outcome phenotype separately, as well as a conjunctional cFDR (ccFDR) threshold for both phenotypes together. Using a moderately conservative threshold, we identified a total of 11 novel single nucleotide polymorphisms (SNPs), six of which were associated with chronic pain grade and nine of which were associated with MDD. Four SNPs on chromosome 14 were associated with both chronic pain grade and MDD. SNPs associated only with chronic pain grade were located within SLC16A7 on chromosome 12. SNPs associated only with MDD were located either in a gene-dense region on chromosome 1 harbouring LINC01360, LRRIQ3, FPGT and FPGT-TNNI3K, or within/close to LRFN5 on chromosome 14. The SNPs associated with both outcomes were also located within LRFN5. Several of the SNPs on chromosomes 1 and 14 were identified as being associated with expression levels of nearby genes in the brain and central nervous system. Overall, using the cFDR approach, we identified several novel genetic loci associated with chronic pain and we describe likely pleiotropic effects of a recently identified MDD locus on chronic pain.Author SummaryGenetic variants explaining variation in complex traits can often be associated with more than one trait at once (‘pleiotropy’). Taking account of this pleiotropy in genetic studies can increase power to find sites in the genome harbouring trait-associated variants. In this study we used the suspected underlying pleiotropy between chronic pain and major depressive disorder to discover novel variants associated with chronic pain, and to investigate genetic variation that may be shared between the two disorders.

scholarly journals Diagnosing Depression in Chronic Pain Patients: DSM-IV Major Depressive Disorder vs. Beck Depression Inventory (BDI)

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0151982 ◽  
Author(s):  
Peter Knaster ◽  
Ann-Mari Estlander ◽  
Hasse Karlsson ◽  
Jaakko Kaprio ◽  
Eija Kalso
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Beck Depression Inventory ◽  
Major Depressive ◽  
Chronic Pain Patients ◽  
Dsm Iv ◽  
Pain Patients

Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain

Medical Care ◽  
2017 ◽  
Vol 55 (2) ◽  
pp. 111-116 ◽  
Author(s):  
Jill A. Bell ◽  
Marco daCosta DiBonaventura ◽  
Edward A. Witt ◽  
Rami Ben-Joseph ◽  
Bryce B. Reeve
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Health Survey ◽  
Population Based ◽  
Major Depressive

scholarly journals Repetitive transcranial magnetic stimulation treatment of major depressive disorder and comorbid chronic pain: response rates and neurophysiologic biomarkers

2021 ◽  
pp. 1-10
Author(s):  
Juliana Corlier ◽  
Reza Tadayonnejad ◽  
Andrew C Wilson ◽  
Jonathan C Lee ◽  
Katharine G Marder ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Major Depressive Disorder ◽  
Transcranial Magnetic Stimulation ◽  
Depressive Disorder ◽  
Magnetic Stimulation ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Phase Coherence ◽  
Pain Severity ◽  
Major Depressive ◽  
Pain Symptoms

Abstract Background Major depressive disorder (MDD) and chronic pain are highly comorbid, and pain symptoms are associated with a poorer response to antidepressant medication treatment. It is unclear whether comorbid pain also is associated with a poorer response to treatment with repetitive transcranial magnetic stimulation (rTMS). Methods 162 MDD subjects received 30 sessions of 10 Hz rTMS treatment administered to the left dorsolateral prefrontal cortex (DLPFC) with depression and pain symptoms measured before and after treatment. For a subset of 96 patients, a resting-state electroencephalogram (EEG) was recorded at baseline. Clinical outcome was compared between subjects with and without comorbid pain, and the relationships among outcome, pain severity, individual peak alpha frequency (PAF), and PAF phase-coherence in the EEG were examined. Results 64.8% of all subjects reported pain, and both depressive and pain symptoms were significantly reduced after rTMS treatment, irrespective of age or gender. Patients with severe pain were 27% less likely to respond to MDD treatment than pain-free individuals. PAF was positively associated with pain severity. PAF phase-coherence in the somatosensory and default mode networks was significantly lower for MDD subjects with pain who failed to respond to MDD treatment. Conclusions Pain symptoms improved after rTMS to left DLPFC in MDD irrespective of age or gender, although the presence of chronic pain symptoms reduced the likelihood of treatment response. Individual PAF and baseline phase-coherence in the sensorimotor and midline regions may represent predictors of rTMS treatment outcome in comorbid pain and MDD.

Sign in / Sign up

Export Citation Format

Share Document